Articles tagged with Antiinflammatory Drugs
A research team at VIB has identified a new anti-inflammatory mechanism of the protein A20, which can help treat autoimmune diseases like Rheumatoid Arthritis. By understanding how A20 interacts with signaling pathways, scientists can develop new therapies to combat inflammation and disrupt the immune system's attack on its own tissues.
Researchers have shown that a new class of anti-inflammatory agents, called IDR peptides, could increase survival from severe clinical malaria when used in combination with antimalarial drugs. In mouse models infected with the Plasmodium berghei parasite, these treatments prevented inflammation and improved survival.
A new study from the University of Pennsylvania School of Medicine confirms that COX-2 inhibitors, such as Vioxx and Celebrex, increase cardiovascular risk by disrupting prostacyclin production. This disruption leads to hardening of the arteries and amplifies the effects of COX-2 inhibition on the cardiovascular system.
A new study found that decreasing adherence to gastroprotective agent (GPA) prescriptions among users of COX-2 inhibitors is linked to an increased risk of upper GI complications. Low GPA adherers had a higher risk of gastrointestinal complications compared to full adherers.
Researchers at Salk Institute find connection between cryptochromes and glucocorticoid receptors to regulate sugar metabolism, potentially avoiding side effects of asthma, allergies, and arthritis drugs. The discovery may lead to new therapies targeting the biological clock.
A University at Buffalo study found exenatide to have a rapid and powerful anti-inflammatory effect, which occurred independently of weight loss in obese type 2 diabetics. The drug also showed a significant drop in average blood sugar levels over three months.
A Mayo Clinic study of 1,382 procedures found no increased risk of bleeding in patients taking anti-clotting drugs during removal of precancerous lesions. Bleeding was more common when procedures were performed on the esophagus and stomach, but not linked to medication use.
Researchers at Salk Institute discover a protein that defends against cancer also plays a key role in steroids' anti-inflammatory action. Targeting this protein could lead to new drugs without steroid side effects. The study suggests some cancer patients may not need steroid treatment due to genetic mutations.
A Stanford study on cox-2 inhibitors may lead to new stroke treatments by increasing blood flow and enhancing recovery. The research also sheds light on why some drugs failed to live up to their promise, revealing that blocking a specific receptor can be beneficial.
A large-scale study found that saw palmetto extract did not improve lower urinary tract symptoms in men with prostate enlargement. The researchers tested up to three times the standard dose and discovered no measurable benefits or toxicity.
A new analysis of non-steroidal anti-inflammatory drugs (NSAIDs) found that naproxen and low-dose ibuprofen have a lower risk of cardiovascular events. In contrast, diclofenac increases the risk, even at non-prescription doses.
Researchers discovered that ibuprofen and other NSAIDs selectively block endocannabinoid metabolism, potentially leading to new analgesic medications with fewer side effects. This finding raises the possibility of targeting inflammation and pain without the gastrointestinal and cardiovascular risks associated with traditional NSAIDs.
Researchers at Douglas Mental Health University Institute are launching the world's first prevention study on Alzheimer's disease. They will recruit 250 healthy adults aged 60 or over with a family history of the condition and observe their biomarkers for ten years to find preventative agents.
A McMaster University study found that stomach acid-suppressing drugs used to treat arthritis may cause damage to the small intestine, aggravating ulcers. The researchers suggest using probiotics as a potential cure for this damage.
A new study has developed a simple process to separate sugars from carrier molecules and attach them to drugs, promising to accelerate the development of novel pharmaceuticals. The technique also allows for easy screening of transformed molecules, which could lead to the production of effective treatments for various diseases.
Researchers found that curcumin can suppress inflammation in tendon diseases, potentially reducing reliance on NSAIDs. This natural compound could be used to treat tendinitis and other inflammatory conditions.
Research found that outpatient electronic prescribing systems do not significantly reduce medication errors, with over 12% of prescriptions containing mistakes. The most common errors were related to missing information and involved anti-inflammatory drugs, antibiotics, nervous system drugs, and cardiovascular drugs.
Researchers at Rockefeller University found that anti-inflammatory drugs decrease the efficacy of selective serotonin reuptake inhibitors (SSRIs) in treating depression and obsessive-compulsive disorder. The study suggests that this may be due to the overlap between depression, inflammation, and Alzheimer's disease.
Researchers at WashU Medicine have identified a low-dose, two-drug cocktail that reduces hearing loss in mice when given before exposure to loud noise. The combination of anticonvulsant and glucocorticoid drugs shows comparable hearing protection at lower doses than when administered alone.
23andMe is conducting a web-based research project to validate its platform for pharmacogenomics research, with a goal of identifying novel genetic associations for drug response. The study aims to replicate previously known associations and search for unknown genetic factors related to response to three classes of drugs.
Researchers have identified a key inhibitory role for the IL-1 signaling pathway in the human innate immune system, revealing its impact on inflammatory bowel disease (IBD) and anti-inflammatory cytokine production. The study suggests that certain drugs used to treat conditions like rheumatoid arthritis may be harmful to IBD patients.
Researchers found that opioid users experienced higher rates of serious adverse events, such as fractures and cardiac risks, compared to those taking coxibs or non-steroidal anti-inflammatory drugs. The study suggests that opioids may be associated with greater cardiovascular risk than other analgesics.
A research project at the Peninsula Medical School in Exeter has won a £140,000 grant to study the effect of hydrogen sulfide as an anti-inflammatory agent. The study found that slow and sustained delivery of H2S reduces inflammation by increasing levels of the body's own anti-inflammatory molecules.
Researchers examined the impact of uninterrupted clopidogrel on postpolypectomy bleeding rates and found a significant increase in risk when used with aspirin/nonsteroidal anti-inflammatory drugs, but the overall outcome is favorable and the risk is small.
Rush University Medical Center is conducting an international clinical trial to test celecoxib's effectiveness in preventing precancerous polyps in children with familial adenomatous polyposis. The five-year study aims to assess whether the drug can reduce or prevent polyp formation, offering hope for these patients.
Researchers found that anti-inflammatory drugs can preserve kidney function in hypertensive rats by regulating blood pressure on tiny filters called glomeruli. The study aims to understand how kidneys autoregulate pressure and explore the role of inflammatory factors in arteriole dysregulation.
Researchers have created a two-in-one formula combining an antibiotic and anti-inflammatory drug, delivered via nano-sized particles that extend medication duration. This development holds promise for easier treatment of bacterial keratitis, potentially reducing hospitalization rates.
A novel anti-inflammatory drug, ATB-346, has shown promise in relieving inflammation symptoms while reducing bleeding and intestinal damage caused by commonly used NSAIDs. The researchers found that ATB-346 is at least as effective as naproxen in animal models and is significantly safer.
A new study at Ben-Gurion University reveals that taking coxib medications like Celebrex with aspirin increases the risk of cardiovascular events. Researchers found that coxibs interfere with aspirin's effectiveness in preventing blood clots, potentially offsetting its protective benefits.
NSAID misuse can lead to severe risks such as stomach ulcers and cardiovascular problems. Experts recommend taking these drugs only after injury and in recommended dosages to avoid potential harm.
Researchers have discovered that anti-inflammatory drugs used to treat arthritis can shrink lymphoma tumors in mice. The study strengthens evidence for a link between inflammation and cancer, suggesting a new way to curb the malignancy of this type of lymphoma.
A new molecule has been synthesized to release hydrogen sulfide gas in a slow and sustained manner, reducing inflammation and increasing levels of the body's own anti-inflammatory molecules. This breakthrough could pave the way for the development of novel approaches to treating inflammatory disorders.
Researchers have discovered that proton pump inhibitors, commonly used to treat ulcers, have significant neuroprotective properties and can enhance the effects of ibuprofen when used together. This finding suggests a new treatment potential for Alzheimer's disease.
Researchers have developed antedrugs that effectively reduce inflammation without causing damage, surpassing the potency of conventional steroids. The new compounds, isoxazoline derivatives, were five times more potent in binding affinities to cell receptors and reducing inflammation.
Researchers developed tiny polymer beads that release anti-inflammatory drugs, breaking down into non-toxic components. The particles reduce inflammation and scarring, cutting the area of scar tissue in half and boosting heart function by 10 percent weeks later.
The study demonstrates that CNI-1493 protects nerve cells against amyloid beta-induced damage in culture and improves memory and cognitive function in mice prone to developing an Alzheimer's-like disease. The drug may provide a faster and more effective treatment for Alzheimer's, offering a promising alternative to current therapies.
A study published by the American Academy of Neurology found that people who use barbiturates and opioids for only eight days a month are twice as likely to develop chronic migraine. The study suggests strict limits on these medications for people with migraine to prevent migraine progression.
A new study published in Arthritis Care & Research found that taking two NSAIDs was associated with lower scores on a health-related quality of life assessment. Dual use was also linked to worse physical functioning and symptoms, highlighting the need for better pain management and patient communication.
Researchers at K-State are examining how nonsteroidal anti-inflammatory drugs damage the gastrointestinal tract. They found that in addition to blocking COX, NSAIDs also affect calpains, important enzymes required for cell maintenance.
Three new drugs for rheumatoid arthritis have been approved, offering improved treatment options with reduced side effects and increased effectiveness. Rituximab, abatacept, and tocilizumab target different pathways to reduce inflammation and symptoms.
A study assessed whether adding succinobucol, a novel agent with antioxidant and anti-inflammatory properties, to optimal medical therapy reduces coronary events and death. The trial achieved a 19% relative risk reduction in hard atherosclerotic clinical endpoints, including cardiovascular death, myocardial infarction, and stroke.
Research suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of developing esophageal adenocarcinoma in patients with Barrett's esophagus. The study found a significant protective effect in patients with multiple genetic abnormalities.
Researchers at UW-Madison have created a novel glass that is stronger and more stable than traditional glass using a new glass-making technique. The new glass has potential medical applications, including the development of pharmaceutical compounds previously unusable due to instability.
A more restrictive drug coverage policy in British Columbia resulted in lower upper gastrointestinal bleeding rates compared to Ontario. The study suggests that limiting access to NSAIDs like coxibs can protect the population from adverse effects.
The MEDAL trial found that etoricoxib and diclofenac have similar heart attack and stroke rates, but different side-effect profiles. Etoricoxib reduces gastrointestinal bleeding risk but may increase cardiovascular events.
Researchers found that turmeric extract inhibited joint destruction and inflammation, altering gene expression and preventing osteoclast activation. A dose of 1.5 milligrams per day may be effective for humans, suggesting a potential mechanism similar to anti-inflammatory drugs.
The University of Cincinnati has developed a faster approach to informing consumers online when the FDA withdraws a medication. The new system, using NetWellness.org, allows for updates in under 24 hours following an FDA announcement.
Healthcare providers must weigh benefits and risks of NSAID use, which are associated with gastrointestinal complications. The AGA Institute recommends lower-risk agents and gastroprotection methods for patients at high risk of GI complications.
A new study published in the British Medical Journal suggests that routine use of anti-inflammatory drugs following hip replacement surgery may do more harm than good. The study found that patients taking ibuprofen for 14 days after surgery reported no significant reductions in hip pain or physical disability.
Researchers analyzed 19 trials involving 33,826 patients and found that long-acting beta-agonists like salmeterol and formoterol increase the risk of asthma-related deaths by 3.5 times and hospitalizations by 2.5 times compared to placebo.
A Queen's University study discovered a new heterodimer formed by COX-1 and COX-2 enzymes in genetically modified mice. This finding may impact the development of alternative anti-inflammatory drugs, potentially reducing cardiovascular risks associated with existing pain medications.
Researchers found that combining an anti-inflammatory with an acid-reducing drug reduces dyspepsia occurrence by 66 percent, compared to taking an over-the-counter anti-inflammatory alone. The study suggests this combination may be the preferred treatment for arthritis patients at high risk for stomach problems.
Researchers found that galantamine, a drug already approved for Alzheimer's disease, can be used as an anti-inflammatory agent. By blocking the enzyme that destroys acetylcholine, galantamine stimulates nerve cells in the brain to release more of the chemical messenger.
Pooled data from clinical trials showed significantly fewer patients taking Nexium developed an ulcer compared to those on placebo. The study demonstrated reduced stomach ulcer risk in patients at high risk for complications associated with NSAID use.
William Fenical, a Scripps Institution of Oceanography professor, has been awarded the Ernest Guenther Award for his pioneering work on marine natural products chemistry. His research has led to the discovery of potent anticancer agents and anti-inflammatory drugs from ocean sea floor bacteria.
Patients with asthma often view their condition as a temporary health problem, leading to inadequate treatment and poor disease control. A study found that nearly half of hospitalised asthma patients believed they only had asthma when symptoms appeared.
Researchers argue that COX-2 inhibitors, including Vioxx, are as effective as traditional NSAIDs but carry fewer gastric side effects. They suggest these drugs may be the best option for some patients without cardiovascular risk factors who cannot tolerate traditional NSAIDs.
A promising new therapy has been approved by the FDA for patients with moderate to severe ulcerative colitis, offering improved lives through reduced inflammation and increased mobility. Nearly 70% of patients experienced clinical response and remission within a year of treatment.
A study of 4,975 patients found that short-term NSAID use does not increase the risk of heart attack. Long-term NSAID use, particularly for over a year, may slightly raise this risk. The findings also suggest individual NSAIDs have varying cardiovascular effects.
Researchers have confirmed that methotrexate and leflunomide are safe and effective treatments for children with severe juvenile rheumatoid arthritis. The study found a higher response rate in children compared to adults, providing new hope for families affected by this chronic disease.